Subscribe To
galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld
Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) ...
November 3, 2023, 12:00 pm
galectin therapeutics to participate in the h.c. wainwright 7th annual nash investor conference on october 24, 2023
NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 23, 2023, 8:00 am
galectin therapeutics to present update on its belapectin liver cirrhosis program at the 20th edition of discovery on target meeting, in boston, september 25-28, 2023
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics, Inc. (NASDAQ: GALT), the lea...
September 26, 2023, 8:00 am
galectin therapeutics to participate in the h.c. wainwright 25th annual global investment conference on september 13, 2023
NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leadin...
September 13, 2023, 5:22 pm
galectin therapeutics to participate in the h.c. wainwright 25th annual global investment conference on september 13, 2023
NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leadin...
September 11, 2023, 8:00 am
galectin therapeutics to present data on liver cirrhosis at the 9th edition of the paris nash meeting, at institut pasteur, september 7th & 8th 2023
NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leadin...
September 7, 2023, 12:00 pm
Galecto to present at investor conferences in september
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in ...
August 31, 2023, 11:00 am
What makes galectin therapeutics inc. (galt) a new buy stock
galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, w...
August 17, 2023, 1:17 pm
Galecto announces topline results from phase 2b galactic-1 trial of gb0139 for the treatment of idiopathic pulmonary fibrosis
Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a...
August 15, 2023, 11:30 am
Galecto reports first quarter operating and financial results
BOSTON, April 28, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in ...
April 28, 2023, 12:00 pm
Bioxytran's positive phase 2 trial results featured in ‘vaccines' peer-reviewed journal
Bioxytran said positive top-line safety and efficacy results from the company's randomized, placebo-controlled Phase 2 clinical trial of its drug can...
March 29, 2023, 4:04 pm
galectin therapeutics to present at 6th obesity & nash drug development summit
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
November 28, 2022, 8:00 am
galectin: ability to potentially target unmet medical need
Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in ...
July 11, 2022, 4:16 pm
Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 3:39 pm
Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 3:39 pm
Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 3:39 pm
Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 3:39 pm
Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 3:39 pm
galectin therapeutics to participate in the h.c. wainwright 23rd annual global investment conference
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 1:55 pm
galectin therapeutics to participate in the h.c. wainwright 23rd annual global investment conference
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...
October 5, 2021, 1:55 pm